A systematic review of 112 patients found that PET scans using RGD peptide tracers — which target blood vessel growth on tumors — detected brain cancers more clearly than standard FDG-PET and could predict treatment response.
Superior tumor-to-background ratioRGD peptide PET tracers outperformed standard FDG-PET for brain tumor detection by targeting tumor blood vessel growth rather than glucose metabolism
What the researchers found
Across 8 studies including 112 patients with primary and secondary brain tumors, RGD peptide PET tracers targeting αvβ3 integrin demonstrated several advantages:
- Superior tumor-to-background ratios compared to standard [¹⁸F]FDG PET, enabling better detection of brain tumors against the naturally high glucose metabolism of brain tissue
- Strong correlation between integrin expression on tumors and tracer uptake in studies with histopathological validation
- Ability to predict treatment response: significant reductions in SUVmax (maximum standardized uptake value) after chemoradiotherapy and bevacizumab were linked to better patient prognosis
- Zero adverse events related to the radiotracers across all studies
Why it matters
Standard FDG-PET scans struggle with brain tumors because healthy brain tissue also has high glucose uptake, making it hard to distinguish tumor from normal tissue. RGD peptide tracers target angiogenesis — the new blood vessel growth that feeds tumors — providing a signal that's much more specific to cancer. This could improve diagnosis, surgical planning, and monitoring of treatment effectiveness for one of the deadliest cancer types.
How the study worked
The researchers conducted a systematic literature search of PubMed, EMBASE, and Cochrane Library through November 2024. They included studies using RGD-based PET tracers in neuro-oncological imaging. Data on demographics, tumor types, imaging protocols, and outcomes were extracted. Study quality was assessed using QUADAS-2, the standard tool for evaluating diagnostic accuracy studies.
What this study cannot tell us
Only 8 studies with 112 total patients were included — a small evidence base. Few studies included histopathological validation to confirm that tracer uptake truly reflected integrin expression. RGD PET tracers don't cross the blood-brain barrier, raising questions about whether some of the signal comes from nonspecific accumulation where the barrier is disrupted by the tumor rather than specific integrin binding. No randomized controlled trials were available.
How to read the evidence
This is a systematic review using QUADAS-2 quality assessment, which is methodologically rigorous. However, it includes only 8 small studies (112 patients total) with no RCTs, and limited histopathological validation, placing it as moderate-strength evidence.
When this study was published
Published in 2025 with literature searches through November 2024, this is the most current systematic review of RGD peptide PET imaging in neuro-oncology.
The bigger picture
Peptide-based molecular imaging is an expanding field that uses small peptide tracers to visualize specific biological processes in living patients. RGD peptides targeting integrins are among the most studied peptide imaging agents, with applications beyond brain tumors in breast cancer, head and neck cancer, and cardiovascular disease. This review adds to evidence that peptide PET tracers can complement or surpass traditional metabolic imaging, moving toward more precise, biology-driven cancer diagnosis.
Questions still open
- Could RGD peptide PET imaging replace MRI for monitoring brain tumor treatment response in routine clinical practice?
- How much of the RGD tracer signal in brain tumors comes from blood-brain barrier disruption versus specific integrin binding?
- Would combining RGD peptide PET with standard MRI improve surgical planning for brain tumor resection?
Common questions
What are RGD peptides and why are they useful for brain tumor imaging?
Could RGD PET scans tell if brain cancer treatment is working?
Read the original research
Advances in clinical neuro-oncology research on integrin PET imaging.
EJNMMI reports, 9(1), 33
Citation
Henssen, Dylan; Herings, Siem; Sabri, Osama; Hesse, Swen; van der Kolk, Anja; Arens, Anne; Gotthardt, Martin. (2025). Advances in clinical neuro-oncology research on integrin PET imaging.. EJNMMI reports, 9(1), 33. https://doi.org/10.1186/s41824-025-00270-8